Going To The Angels: Independent Investors Back $16M Series B For Savara
This article was originally published in The Pink Sheet Daily
Executive Summary
Savara Pharmaceuticals will finance an 80-patient Phase II trial for its inhaled vancomycin candidate as a treatment for MRSA infections in cystic fibrosis patients. Such infections have been linked with a six-year reduction in life expectancy.
You may also be interested in...
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
Savara Inc.
Savara's NanoCluster dry powder aerosol drug delivery platform has potential for local or systemic delivery of a wide variety of drugs. Savara says that since it can precisely tailor its microparticles' sizes, it will improve aerosol efficiency, and thus will be able to deliver two to three times more drug to the lung than competitors' products.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.